Protagenic Therapeutics (PTIX) announced that warrant exchanges and exercises over the last four trading days have generated $3.1M in cash. The proceeds will fund working-capital needs and advance the Company’s peptide-based drug candidates for stress-related and central-nervous-system disorders.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PTIX:
- Protagenic Therapeutics Issues Common Stock for Warrants
- Protagenic Therapeutics Completes Acquisition of Phytanix Bio
- Protagenic Therapeutics, Phytanix Bio to combine in all-stock transaction
- Protagenic Therapeutics, Phytanix Bio enter business combination agreement
- Biotech Alert: Searches spiking for these stocks today